Document Detail


Effects of fenofibrate and gemfibrozil on plasma homocysteine.
MedLine Citation:
PMID:  11454380     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fenofibrate increases plasma homocysteine. Because the concentration of plasma homocysteine depends on renal function, we postulate that increases in plasma homocysteine are a result of the known impairment of renal function caused by fenofibrate. Gemfibrozil, another fibrate, does not affect renal function. In a crossover study we tested whether gemfibrozil would raise homocysteine. 22 patients who had hypertriglyceridaemia were given 900 mg gemfibrozil or 200 mg fenofibrate daily for 6 weeks. Lipids were altered similarly, but homocysteine, creatinine, and cystatin C were raised by fenofibrate but not by gemfibrozil (p for differences between treatment effects: 0.007, 0.006, and 0.040, respectively). We propose gemfibrozil should be the fibrate of choice.
Authors:
S Westphal; J Dierkes; C Luley
Publication Detail:
Type:  Clinical Trial; Comparative Study; Letter; Randomized Controlled Trial    
Journal Detail:
Title:  Lancet     Volume:  358     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-07-16     Completed Date:  2001-07-26     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-40     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Creatinine / blood
Cross-Over Studies
Cystatin C
Cystatins / blood
Gemfibrozil / adverse effects*,  therapeutic use
Homocysteine / blood*
Humans
Hypertriglyceridemia / blood,  drug therapy*
Lipids / blood
Male
Middle Aged
Procetofen / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/CST3 protein, human; 0/Cystatin C; 0/Cystatins; 0/Lipids; 25812-30-0/Gemfibrozil; 454-28-4/Homocysteine; 49562-28-9/Procetofen; 60-27-5/Creatinine
Comments/Corrections
Comment In:
Lancet. 2001 Nov 24;358(9295):1811-2   [PMID:  11734262 ]
Lancet. 2001 Nov 24;358(9295):1811; author reply 1811-2   [PMID:  11734263 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence for a cerebral effect of the hepatitis C virus.
Next Document:  How immunology is reshaping clinical disciplines: the example of haematology.